Kyle Jackson, BHSc
Graduated from McMaster University with a BHSc in Biomedical Discovery and Commercialization. Specialized in strategic business development focusing on novel biologic therapeutics and translational research. I have consulted for several Life Sciences startup companies compiling market intelligence and advising them on their commercialization and regulatory pathways.
My research explores the use of phage therapeutics to combat microbiome-based infections. I investigate phage-based methods of modulating the gut microbiome to prevent opportunistic pathogens from colonizing and inducing inflammation. It is my goal to develop comprehensive preclinical models to assess the efficacy of phage therapy candidates for use in the gut microbiome environment.
Tags
- Producing phages consistently: then and now This week, Kyle Jackson tackles phage manufacturing. He first enlightens us on how phages have historically been produced and preserved. Then, through a chat with Frenk Smrekar and Barbara Hubad, we learn how JAFRAL helps companies and…
- Overcoming barriers to phage commercialization: a conversation with leaders at Cytophage and BiomX This week, McMaster University PhD student Kyle Jackson interviews Cytophage and BiomX executives, who share phage therapy commercialization challenges and progress and a sneak peek into what they'll present at Phage Futures.
You can also…
- Making your company go viral: Adaptive Phage Therapeutics This week, Kyle Jackson (PhD student at McMaster University) brings us a profile of Adaptive Phage Therapeutics, the clinical-stage phage biotech company commercializing the US Navy's phage collection. This is the first in a new column Kyle…
